참고문헌
- Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011;186:1830-4. https://doi.org/10.1016/j.juro.2011.06.057
- Tufan ZK, Bulut C, Yazan T, Hatipoglu C, Erdinc S, Kinikli S, et al. A life-threatening Escherichia coli meningitis after prostate biopsy. Urol J 2011;8:69-71.
- Wolf JS Jr, Bennett CJ, Dmochowski RR, Hollenbeck BK, Pearle MS, Schaeffer AJ; Urologic Surgery Antimicrobial Prophylaxis Best Practice Policy Panel. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol 2008;179:1379-90. https://doi.org/10.1016/j.juro.2008.01.068
- Cek M, Tandogdu Z, Naber K, Tenke P, Wagenlehner F, van Oostrum E, et al. Antibiotic prophylaxis in urology departments, 2005-2010. Eur Urol 2013;63:386-94. https://doi.org/10.1016/j.eururo.2012.09.038
- Feliciano J, Teper E, Ferrandino M, Macchia RJ, Blank W, Grunberger I, et al. The incidence of fluoroquinolone resistant infections after prostate biopsy--are fluoroquinolones still effective prophylaxis? J Urol 2008;179:952-5; discussion 955. https://doi.org/10.1016/j.juro.2007.10.071
- Horcajada JP, Busto M, Grau S, Sorli L, Terradas R, Salvado M, et al. High prevalence of extended-spectrum beta-lactamaseproducing enterobacteriaceae in bacteremia after transrectal ultrasound-guided prostate biopsy: a need for changing preventive protocol. Urology 2009;74:1195-9. https://doi.org/10.1016/j.urology.2009.06.061
- Chung HS, Hwang EC, Yu HS, Jung SI, Lee SJ, Lim DH, et al. Prevalence of fluoroquinolone-resistant rectal flora in patients undergoing transrectal ultrasound-guided prostate needle biopsy: a prospective multicenter study. Int J Urol 2018;25:278-83. https://doi.org/10.1111/iju.13511
- Ozden E, Bostanci Y, Yakupoglu KY, Akdeniz E, Yilmaz AF, Tulek N, et al. Incidence of acute prostatitis caused by extendedspectrum beta-lactamase-producing Escherichia coli after transrectal prostate biopsy. Urology 2009;74:119-23. https://doi.org/10.1016/j.urology.2008.12.067
- Batura D, Rao GG, Bo Nielsen P, Charlett A. Adding amikacin to fluoroquinolone-based antimicrobial prophylaxis reduces prostate biopsy infection rates. BJU Int 2011;107:760-4. https://doi.org/10.1111/j.1464-410X.2010.09715.x
- Kehinde EO, Al-Maghrebi M, Sheikh M, Anim JT. Combined ciprofloxacin and amikacin prophylaxis in the prevention of septicemia after transrectal ultrasound guided biopsy of the prostate. J Urol 2013;189:911-5. https://doi.org/10.1016/j.juro.2012.08.237
- Adibi M, Hornberger B, Bhat D, Raj G, Roehrborn CG, Lotan Y. Reduction in hospital admission rates due to post-prostate biopsy infections after augmenting standard antibiotic prophylaxis. J Urol 2013;189:535-40. https://doi.org/10.1016/j.juro.2012.08.194
- Adibi M, Pearle MS, Lotan Y. Cost-effectiveness of standard vs intensive antibiotic regimens for transrectal ultrasonography (TRUS)-guided prostate biopsy prophylaxis. BJU Int 2012;110:E86-91. https://doi.org/10.1111/j.1464-410X.2011.10768.x
- Zani EL, Clark OA, Rodrigues Netto N Jr. Antibiotic prophylaxis for transrectal prostate biopsy. Cochrane Database Syst Rev 2011;(5):CD006576.
- Marino K, Parlee A, Orlando R, Lerner L, Strymish J, Gupta K. Comparative effectiveness of single versus combination antibiotic prophylaxis for infections after transrectal prostate biopsy. Antimicrob Agents Chemother 2015;59:7273-5. https://doi.org/10.1128/AAC.01457-15
- Batura D, Rao GG, Nielsen PB. Prevalence of antimicrobial resistance in intestinal flora of patients undergoing prostatic biopsy: implications for prophylaxis and treatment of infections after biopsy. BJU Int 2010;106:1017-20. https://doi.org/10.1111/j.1464-410X.2010.09294.x
- Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010;183:963-8. https://doi.org/10.1016/j.juro.2009.11.043
- Taylor AK, Zembower TR, Nadler RB, Scheetz MH, Cashy JP, Bowen D, et al. Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care. J Urol 2012;187:1275-9. https://doi.org/10.1016/j.juro.2011.11.115
- Duplessis CA, Bavaro M, Simons MP, Marguet C, Santomauro M, Auge B, et al. Rectal cultures before transrectal ultrasoundguided prostate biopsy reduce post-prostatic biopsy infection rates. Urology 2012;79:556-61. https://doi.org/10.1016/j.urology.2011.09.057
-
Tsu JH, Ma WK, Chan WK, Lam BH, To KC, To WK, et al. Prevalence and predictive factors of harboring fluoroquinoloneresistant and extended-spectrum
${\beta}$ -lactamase-producing rectal flora in Hong Kong Chinese men undergoing transrectal ultrasound-guided prostate biopsy. Urology 2015;85:15-21. https://doi.org/10.1016/j.urology.2014.07.078 - Unnikrishnan R, El-Shafei A, Klein EA, Jones JS, Kartha G, Goldman HB. For single dosing, levofloxacin is superior to ciprofloxacin when combined with an aminoglycoside in preventing severe infections after prostate biopsy. Urology 2015;85:1241-6. https://doi.org/10.1016/j.urology.2014.12.062
- Miyazaki Y, Akamatsu S, Kanamaru S, Kamiyama Y, Sengiku A, Iguchi R, et al. A prospective randomized trial comparing a combined regimen of amikacin and levofloxacin to levofloxacin alone as prophylaxis in transrectal prostate needle biopsy. Urol J 2016;13:2533-40.
- Gopal Rao G, Batura D. Emergency hospital admissions attributable to infective complications of prostate biopsy despite appropriate prophylaxis: need for additional infection prevention strategies? Int Urol Nephrol 2014;46:309-15. https://doi.org/10.1007/s11255-013-0529-5
- Son KC, Chung HS, Jung SI, Kim MS, Hwang EC, Kim JW, et al. Trial comparing a combined regimen of amikacin and ciprofloxacin to ciprofloxacin alone as transrectal prostate biopsy prophylaxis in the era of high fluoroquinolone-resistant rectal flora. J Korean Med Sci 2018;33:e113. https://doi.org/10.3346/jkms.2018.33.e113
- Kanafani ZA, Mehio-Sibai A, Araj GF, Kanaan M, Kanj SS. Epidemiology and risk factors for extended-spectrum betalactamase-producing organisms: a case control study at a tertiary care center in Lebanon. Am J Infect Control 2005;33:326-32. https://doi.org/10.1016/j.ajic.2005.03.009
- Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001;32:1162-71. https://doi.org/10.1086/319757
- Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Bilker WB, Lautenbach E. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum betalactamase-producing enterobacteriaceae: variability by site of infection. Arch Intern Med 2005;165:1375-80. https://doi.org/10.1001/archinte.165.12.1375
- Hwang EC, Jung SI, Seo YH, Jeong SH, Kwon DD, Park K, et al. Risk factors for and prophylactic effect of povidone-iodine rectal cleansing on infectious complications after prostate biopsy: a retrospective cohort study. Int Urol Nephrol 2015;47:595-601. https://doi.org/10.1007/s11255-015-0931-2
- Ryu JW, Jung SI, Ahn JH, Hwang EC, Yu HS, Kang TW, et al. Povidone-iodine rectal cleansing and targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound-guided prostate biopsy are associated with reduced incidence of postoperative infectious complications. Int Urol Nephrol 2016;48:1763-70. https://doi.org/10.1007/s11255-016-1394-9